Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Attracting Attention: Discovery of IL-8/CXCL8 and the Birth of the Chemokine Field

Bethany B. Moore and Steven L. Kunkel
J Immunol January 1, 2019, 202 (1) 3-4; DOI: https://doi.org/10.4049/jimmunol.1801485
Bethany B. Moore
*Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109;
†Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI 48109; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bethany B. Moore
Steven L. Kunkel
‡Department of Pathology, University of Michigan, Ann Arbor, MI 48109
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

In the days when almost every biomedical science building has ubiquitous posters on the walls highlighting the various chemokines, their receptors, their alternative names, and the cell types they recruit, it is hard to imagine what it was like before these molecules were identified and understood. By the early 1980s, it was appreciated that certain substances could be chemoattractants for inflammatory cells. These substances included the bacterial peptide fMLF, the complement anaphylatoxin C5a, and the lipid mediator leukotriene B4. However, these substances did not show selectivity in their ability to uniquely recruit particular leukocyte subsets. There were hints, however, that neutrophil-specific chemotactic activity did exist. For example, in 1980, Merrill et al. demonstrated that human alveolar macrophages, when activated by adhesion to tissue culture plastic or when stimulated with aggregated IgG or zymosan particles, released a substance that, by gel filtration, had a size of ∼10 kDa and was able to attract neutrophils (1). The chemotactic activity of this substance was sensitive to trypsin, suggesting a protein product, but this activity was not further purified or cloned at the time. Fast forward a few years, and the sequences of the cDNAs encoding IL-1α and IL-1β were both identified (2, 3), paving the way for studies on the effects of rIL-1 on inflammation in vivo and in vitro. By 1984, IL-1, or substances later identified as IL-1, were shown to be induced by LPS stimulation and to have the capacity to promote neutrophil chemotaxis in vitro (4–6). In 1986, it was reported that s.c. injections of IL-1 could cause acute inflammatory responses, including rapid margination of neutrophils in vivo (7). Thus, at this point in time, it appeared that the cytokine IL-1 was a chemoattractant. The breakthroughs in the initial discovery of chemokines came in 1987 with two important collaborative papers.

In August of 1987, a collaborative study between Drs. T. Yoshimura and K. Matsushima working in the laboratories of Drs. E. Leonard and J. Oppenheim at the National Cancer Institute, respectively, showed that highly purified or rIL-1 had no chemotactic activity for neutrophils. Furthermore, the groups demonstrated that the chemotactic activity for neutrophils seen in LPS-stimulated monocytes could be separated from IL-1 and was attributed to a protein of ∼10 kDa (8). In a subsequent paper, which we are highlighting in this Pillars of Immunology series, these same investigators and their colleagues demonstrated that they could purify a substance from LPS-stimulated monocytes using anion exchange chromatography, gel filtration, and HPLC on cation-exchange and reverse-phase columns. This substance as a purified 7 kDa band with an amino acid composition that was unique from IL-1, as determined by N-terminal amino acid sequencing performed by Dr. E. Appella’s laboratory (9). They originally called this substance “human monocyte-derived neutrophil chemotactic factor.” Of importance, this report showed that, at an optimum concentration of 10 nM, the substance could attract human neutrophils with a potency similar to fMLF but showed no ability to attract human monocytes. They also identified what would come to be known as the CXC conserved cysteine residue motif in the N-terminal region of the molecule. Thus, this report originally published in the Proceedings of the National Academy of Sciences USA is regarded as the first identification of the chemotactic cytokine (or chemokine) that would eventually be known as neutrophil-activating protein and, later, IL-8. Given that the significance of this publication at the time was in the identification of a chemokine that was specific for neutrophils, it is somewhat ironic that the impetus to change the name to IL-8 came when it was shown that this same protein could also attract a subset of T cells (10). It should also be noted that the laboratories of Dr. M. Baggilioni (11) and J. Van Damme (12) reported purification of the identical protein shortly after publication by Yoshimura et al. Drs. Yoshimura and Matsushima also went on to independently characterize the monocyte-recruiting activity of the chemokine we now know as MCP-1/MCP-1 or CCL2 (13, 14). Thus, the chemokine field was born.

Over the next several years, the improvements in protein purification and molecular cloning led to the discoveries that the numerous chemotactic substances with unique names, an alphabet soup of abbreviations and a myriad of specificities, were all attributable to the growing family of molecules known as chemokines. It also became appreciated that chemokines act by binding high-affinity seven-transmembrane G protein–coupled receptors, according to the structure of the chemokine subfamilies. In an effort to coalesce and simplify these expanding data, the International Union of Immunologic Societies/World Health Organization Subcommittee on Chemokine Nomenclature recommended a systematic nomenclature based on the conserved cysteine residue structures of the subfamilies (15), which gave IL-8 the designation of CXCL8 and identified its specific receptors as CXCR1 and CXCR2.

Shortly after the discovery that cytokines like IL-1 and TNF-α could induce IL-8/CXCL8 in monocytes, laboratories, including the laboratory of coauthor Dr. Steven L. Kunkel, began to realize that structural cells, such as fibroblasts, endothelial cells, and hepatocytes, could release IL-8/CXCL8 (16–18). It was quickly shown that IL-8/CXCL8 could contribute to host defense but also to inflammatory diseases and neutrophil-mediated tissue damage [reviewed in (19)]. Having access to rIL-8/CXCL8 allowed for studies of IL-8/CXCL8 impact on numerous cell types. Indeed, IL-8/CXCL8 had angiogenic activity on endothelial cells as well (20); the angiogenic activity was mediated by the amino acid motif of glutamic acid, leucine, and arginine (ELR) within the N terminus of the CXC family of chemokines, whereas ELR-negative CXC chemokines were actually angiostatic (reviewed in Ref. 21). Development of Abs against IL-8/CXCL8 allowed for studies using human disease samples, and it became clear that this chemokine was overexpressed in multiple forms of cancer, respiratory diseases, and tissue fibrosis (reviewed in Ref. 22–24). This rapidly expanding literature sparked the interest of coauthor Dr. B. Moore and led her to move to the University of Michigan to work in collaboration with Dr. R. Strieter. Here, they confirmed the importance of ELR+ CXC chemokines in regulating tumorigenesis of prostate cancer cells (25). The idea that chemokines could regulate behaviors of nonmotile structural cells, such as alveolar epithelial cells, led to her work showing the importance of MCP-1/CCL2 and other CCR2 ligands in regulating lung fibrosis (reviewed in Ref. 26). Thus, three decades later, a large number of laboratories, including those of the coauthors, are indebted to the resourceful and collegial collaboration that discovered IL-8/CXCL8 (9) and birthed the field of chemokine biology. We are confident that the next 30 years will yield even more insights into this fascinating family of proteins.

Disclosures

The authors have no financial conflicts of interest.

Footnotes

  • Abbreviation used in this article:

    ELR
    glutamic acid, leucine, and arginine.

  • Copyright © 2018 by The American Association of Immunologists, Inc.

References

  1. ↵
    1. Merrill, W. W.,
    2. G. P.Naegel ,
    3. R. A.Matthay ,
    4. H. Y.Reynolds
    . 1980. Alveolar macrophage-derived chemotactic factor: kinetics of in vitro production and partial characterization. J. Clin. Invest. 65: 268–276.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Auron, P. E.,
    2. A. C. Webb,
    3. L. J. Rosenwasser,
    4. S. F. Mucci,
    5. A. Rich,
    6. S. M. Wolff,
    7. C. A. Dinarello
    . 1984. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc. Natl. Acad. Sci. USA 81: 7907–7911.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Lomedico, P. T.,
    2. U. Gubler,
    3. C. P. Hellmann,
    4. M. Dukovich,
    5. J. G. Giri,
    6. Y. C. Pan,
    7. K. Collier,
    8. R. Semionow,
    9. A. O. Chua,
    10. S. B. Mizel
    . 1984. Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature 312: 458–462.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Luger, T. A.,
    2. J. A. Charon,
    3. M. Colot,
    4. M. Micksche,
    5. J. J. Oppenheim
    . 1983. Chemotactic properties of partially purified human epidermal cell-derived thymocyte-activating factor (ETAF) for polymorphonuclear and mononuclear cells. J. Immunol. 131: 816–820.
    OpenUrlAbstract
    1. Sauder, D. N.,
    2. N. L. Mounessa,
    3. S. I. Katz,
    4. C. A. Dinarello,
    5. J. I. Gallin
    . 1984. Chemotactic cytokines: the role of leukocytic pyrogen and epidermal cell thymocyte-activating factor in neutrophil chemotaxis. J. Immunol. 132: 828–832.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Miossec, P.,
    2. C. L. Yu,
    3. M. Ziff
    . 1984. Lymphocyte chemotactic activity of human interleukin 1. J. Immunol. 133: 2007–2011.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Granstein, R. D.,
    2. R. Margolis,
    3. S. B. Mizel,
    4. D. N. Sauder
    . 1986. In vivo inflammatory activity of epidermal cell-derived thymocyte activating factor and recombinant interleukin 1 in the mouse. J. Clin. Invest. 77: 1020–1027.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Yoshimura, T.,
    2. K. Matsushima,
    3. J. J. Oppenheim,
    4. E. J. Leonard
    . 1987. Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization and separation from interleukin 1 (IL 1). J. Immunol. 139: 788–793.
    OpenUrlAbstract
  8. ↵
    1. Yoshimura, T.,
    2. K. Matsushima,
    3. S. Tanaka,
    4. E. A. Robinson,
    5. E. Appella,
    6. J. J. Oppenheim,
    7. E. J. Leonard
    . 1987. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc. Natl. Acad. Sci. USA 84: 9233–9237.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Larsen, C. G.,
    2. A. O. Anderson,
    3. E. Appella,
    4. J. J. Oppenheim,
    5. K. Matsushima
    . 1989. The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 243: 1464–1466.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Walz, A.,
    2. P. Peveri,
    3. H. Aschauer,
    4. M. Baggiolini
    . 1987. Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes. Biochem. Biophys. Res. Commun. 149: 755–761.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Van Damme, J.,
    2. J. Van Beeumen,
    3. G. Opdenakker,
    4. A. Billiau
    . 1988. A novel, NH2-terminal sequence-characterized human monokine possessing neutrophil chemotactic, skin-reactive, and granulocytosis-promoting activity. J. Exp. Med. 167: 1364–1376.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Yoshimura, T.,
    2. E. A. Robinson,
    3. S. Tanaka,
    4. E. Appella,
    5. J. Kuratsu,
    6. E. J. Leonard
    . 1989. Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J. Exp. Med. 169: 1449–1459.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Matsushima, K.,
    2. C. G. Larsen,
    3. G. C. DuBois,
    4. J. J. Oppenheim
    . 1989. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J. Exp. Med. 169: 1485–1490.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Bacon, K.,
    2. M. Baggiolini,
    3. H. Broxmeyer,
    4. R. Horuk,
    5. I. Lindley,
    6. A. Mantovani,
    7. K. Maysushima,
    8. P. Murphy,
    9. H. Nomiyama,
    10. J. Oppenheim, et al
    . 2002. Chemokine/chemokine receptor nomenclature. J. Interferon Cytokine Res. 22: 1067–1068.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Strieter, R. M.,
    2. S. L. Kunkel,
    3. H. J. Showell,
    4. D. G. Remick,
    5. S. H. Phan,
    6. P. A. Ward,
    7. R. M. Marks
    . 1989. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta. Science 243: 1467–1469.
    OpenUrlAbstract/FREE Full Text
    1. Strieter, R. M.,
    2. S. H. Phan,
    3. H. J. Showell,
    4. D. G. Remick,
    5. J. P. Lynch,
    6. M. Genord,
    7. C. Raiford,
    8. M. Eskandari,
    9. R. M. Marks,
    10. S. L. Kunkel
    . 1989. Monokine-induced neutrophil chemotactic factor gene expression in human fibroblasts. J. Biol. Chem. 264: 10621–10626.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Thornton, A. J.,
    2. R. M. Strieter,
    3. I. Lindley,
    4. M. Baggiolini,
    5. S. L. Kunkel
    . 1990. Cytokine-induced gene expression of a neutrophil chemotactic factor/IL-8 in human hepatocytes. J. Immunol. 144: 2609–2613.
    OpenUrlAbstract
  17. ↵
    1. Atta ur, R.,
    2. K. Harvey,
    3. R. A. Siddiqui
    . 1999. Interleukin-8: an autocrine inflammatory mediator. Curr. Pharm. Des. 5: 241–253.
    OpenUrlPubMed
  18. ↵
    1. Koch, A. E.,
    2. P. J. Polverini,
    3. S. L. Kunkel,
    4. L. A. Harlow,
    5. L. A. DiPietro,
    6. V. M. Elner,
    7. S. G. Elner,
    8. R. M. Strieter
    . 1992. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258: 1798–1801.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Keane, M. P.,
    2. D. A. Arenberg,
    3. B. B. Moore,
    4. C. L. Addison,
    5. R. M. Strieter
    . 1998. CXC chemokines and angiogenesis/angiostasis. Proc. Assoc. Am. Physicians 110: 288–296.
    OpenUrlPubMed
  20. ↵
    1. Waugh, D. J.,
    2. C. Wilson
    . 2008. The interleukin-8 pathway in cancer. Clin. Cancer Res. 14: 6735–6741.
    OpenUrlAbstract/FREE Full Text
    1. Mukaida, N.
    2003. Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am. J. Physiol. Lung Cell. Mol. Physiol. 284: L566–L577.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Sahin, H.,
    2. H. E. Wasmuth
    . 2013. Chemokines in tissue fibrosis. Biochim. Biophys. Acta 1832: 1041–1048.
    OpenUrl
  22. ↵
    1. Moore, B. B.,
    2. D. A. Arenberg,
    3. K. Stoy,
    4. T. Morgan,
    5. C. L. Addison,
    6. S. B. Morris,
    7. M. Glass,
    8. C. Wilke,
    9. Y. Y. Xue,
    10. S. Sitterding, et al
    . 1999. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am. J. Pathol. 154: 1503–1512.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Moore, B. B.
    2014. Following the path of CCL2 from prostaglandins to periostin in lung fibrosis. Am. J. Respir. Cell Mol. Biol. 50: 848–852.
    OpenUrl
PreviousNext
Back to top

In this issue

The Journal of Immunology: 202 (1)
The Journal of Immunology
Vol. 202, Issue 1
1 Jan 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Advertising (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Attracting Attention: Discovery of IL-8/CXCL8 and the Birth of the Chemokine Field
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Attracting Attention: Discovery of IL-8/CXCL8 and the Birth of the Chemokine Field
Bethany B. Moore, Steven L. Kunkel
The Journal of Immunology January 1, 2019, 202 (1) 3-4; DOI: 10.4049/jimmunol.1801485

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Attracting Attention: Discovery of IL-8/CXCL8 and the Birth of the Chemokine Field
Bethany B. Moore, Steven L. Kunkel
The Journal of Immunology January 1, 2019, 202 (1) 3-4; DOI: 10.4049/jimmunol.1801485
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Conceiving the Inconceivable: The Function of Aire in Immune Tolerance to Peripheral Tissue-Restricted Antigens in the Thymus
  • Glial Cells as Regulators of Neuroimmune Interactions in the Central Nervous System
  • The Colon as a Major Site of Immunoregulation by CD4+ T Cell Subsets in the Steady State
Show more PILLARS OF IMMUNOLOGY

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • Public Access
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2021 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606